

<b>Sponsor</b>	<b>Trial</b>
Gamida Cell	GC 02.01.001: A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects with Hematologic Malignancies following Myeloablative Therapy
	<b>Leukemias/MDS</b>
Athersys	GVHD-2007-001: A Phase I, Multicenter, Dose-Escalation Trial Evaluating maximum Tolerated Dose of Single and Repeated Administration of Allogeneic MultiStem in Patients with Acute Leukemia, Chronic Myeloid Leukemia or Myelodysplasia
University of Minnesota	MT2010-06: KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Blood and Marrow Transplant Clinical Trials Network	CTN 0501: MULTI-CENTER, OPEN LABEL, RANDOMIZED TRIAL COMPARING SINGLE VERSUS DOUBLE UMBILICAL CORD BLOOD (UCB) TRANSPLANTATION IN PEDIATRIC PATIENTS WITH HIGH RISK LEUKEMIA AND MYELOYDYSPLASIA
Blood and Marrow Transplant Clinical Trials Network	CTN 0402: A Phase III Randomized, Multicenter Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate as Graft-versus-Host Disease (GvHD) Prophylaxis after HLA-Matched, Related Peripheral Blood Stem Cell Transplantation
Blood and Marrow Transplant Clinical Trials Network	CTN 0901: A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
Center for International Blood and Marrow Transplant	09-MRD: The Role of Minimal Residual Disease Testing before and after Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia
	<b>Lymphoma</b>
Blood and Marrow Transplant Clinical Trials Network	CTN 0701: Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response
Otsuka Pharmaceutical Development & Commercialization, Inc.	273-08-201: A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually-Optimized Conditioning Using Pharmacokinetics [PK]-directed Dose Adjustment of Once Daily Intravenous Busulfan, followed by Autologous Hematopoietic Stem Cell Transplant in Subjects with Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
	<b>Multiple Myeloma</b>
Blood and Marrow Transplant Clinical Trials Network	CTN 0702: A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma
Otsuka Pharmaceutical Development & Commercialization, Inc.	273-08-205: A Phase 2a Study of Once Daily Intravenous Busulfan with Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects with Relapsed Multiple Myeloma after Prior Autologous HSCT
	<b>Non-malignant disorders</b>
Blood and Marrow Transplant Clinical Trials Network	CTN 0301: Fludarabine-based Conditioning for Allogeneic Marrow Transplantation from HLA-compatible Unrelated Donors in Severe Aplastic Anemia

Blood and Marrow Transplant Clinical Trials Network	CTN 0601: Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen
	<b>Neuroblastoma</b>
PBMTC	ONC-032: High dose temozolomide, thiotepa and carboplatin with autologous stem cell rescue (ASCR) followed by continuation therapy with 13-cis-retinoic acid in patients with recurrent/refractory malignant brain tumors
	<b>GVHD</b>
Osiris Therapeutics, Inc.	275: Expanded Access of Prochymal (Ex-Vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute Graft Versus Host Disease (GVHD)
Osiris Therapeutics, Inc.	276: Expanded Access of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD.
Blood and Marrow Transplant Clinical Trials Network	CTN 0801: A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone, Sirolimus/Extracorporeal Photopheresis plus Prednisone, and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease
Blood and Marrow Transplant Clinical Trials Network	CTN 0802: A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids with Mycophenolate Mofetil vs. Corticosteroids with Placebo as Initial Systemic Treatment of Acute GVHD
Fresenius Biotech	IV-ATG-SCT-01: A randomized, prospective, double-blind, placebo-controlled, phase 3 study of study drug prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic graft versus host disease in adult acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome patients after allogeneic stem cell transplantation from unrelated donors
	<b>Other</b>
Center for International Blood and Marrow Transplant	06-DON: A Multicenter Study of Hematopoietic Stem Cell Donor Safety and Quality of Life
Gentium SpA	Defibrotide treatment IND Protocol investigating the use of defibrotide in the treatment of hepatic veno-occlusive disorder
Washington University of Medicine	01-0923: A study of Hematopoietic Stem Cell Transplantation (HSCT) in Non Malignant Disease Using a Reduced Intensity Preparatory Regime with Campath-1H, Fludarabine and Melphalan
Texas Institute of Medicine and Surgery	TIMS001: Observational Study Evaluating Role of Cord Blood Unit Quality and Ethnicity to Transplant Related Outcomes
Chimerix, Inc.	CMX001-202 :A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of <u>A</u> denovirus Disease Following <u>H</u> ematopoietic Stem Cell Transplantation (The ADV HALT Trial)
Primary Immune Deficiency Treatment Consortium	PIDTC 6902: A Retrospective and Cross- Sectional Analysis of Patients Treated for Severe Combined Immunodeficiency (SCID) (1968-2010)
Primary Immune Deficiency Treatment Consortium	PIDTC 6901: A Prospective Natural History Study of Diagnosis, Treatment, and Outcomes of Children with SCID Disorders

Merck Sharp & Dohme Corp.	V212 001-02: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Stem Cell Transplant
Pediatric Blood and Marrow Transplant Consortium AND Thalassemia Clinical Research Network	CRN-NMD 0901: A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Blood and Marrow Transplant Clinical Trials Network	CTN 0903 – Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals